Abstracts tagged "cancer and malignancy"

Abstract Number: 1082 • 2019 ACR/ARP Annual Meeting
Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Eunyoung Lee¹, Kyung-Do Han ², Yeong-Wook Song ³ and Eun Young Lee ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ²Department of Biostatistics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: The aim of this study is to determine the risk of overall malignancy and site-specific cancer in ankylosing spondylitis (AS) patients compared with patients…
Abstract Number: 2840 • 2016 ACR/ARHP Annual Meeting
Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?
Sasha Bernatsky¹, Ann E. Clarke², Rosalind Ramsey-Goldman³, Patrick Gaffney⁴, John Spinelli⁵, Sophia Wang⁶ and Timothy J. Vyse⁷, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³FSM, Northwestern University, Chicago, IL, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁶Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
Are there genetic predispositions to diffuse large B-cell lymphoma (DLBCL) in systemic lupus (SLE)? Sasha Bernatsky1, Ann E. Clarke2, Rosalind Ramsey-Goldman3, Patrick M. Gaffney4,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].